McKesson Corporation MCK
Healthcare · Medical Distribution · United States · S&P 500
Based on the available data, McKesson Corporation gets an algorithmic score of 43/100. It trades at 864.82 $, with a bullish technical trend (RSI 45.3) and 30.4% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (13.4% compound annual).
- Attractive free-cash-flow yield (5.4%).
- Low beta (0.02): defensive profile.
- Meaningful dividend (43.00%).
Weaknesses
- Thin net margin (1.1%): vulnerable to costs.
Fundamentals
| P/E | 23.19 |
| Forward P/E | 17.15 |
| PEG | 1.66 |
| P/B | -23.66 |
| EV/EBITDA | 15.61 |
| P/S | 0.25 |
| ROA % | 4.74 |
| Gross margin % | 3.63 |
| Operating margin % | 1.35 |
| Net margin % | 1.12 |
| Revenue growth % (y/y) | 7.70 |
| Earnings growth % (y/y) | -17.60 |
| Revenue CAGR % | 13.39 |
| Earnings CAGR % | 10.18 |
| Current ratio | 0.89 |
| FCF yield % | 5.37 |
| Dividend yield % | 43.00 |
| Payout % | 8.80 |
Returns
| 1 month | -3.1 % |
| 3 months | +14.6 % |
| 6 months | +0.8 % |
| YTD | +5.3 % |
| 1 year | +14.2 % |
| 3 years | +99.8 % |
| 5 years | +341.3 % |
Risk
| 1-year volatility | 30.4 % |
| Beta | 0.02 |
| 5-year max drawdown | -27.2 % |
| Sharpe 1A | 0.45 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.